TSXV:BTI.H - Post by User
Post by
prophetoffactzon Dec 16, 2022 1:32pm
179 Views
Post# 35176293
panobinostat, lomustine, xB3-bevacizumab
panobinostat, lomustine, xB3-bevacizumabMidatech's lead drug currently in clinical trials is
panobinostat and seeks to bypass the blood-brain barrier directly into the brain tumor. The current clinical trial will study
panobinostat alone and in combination with
lomustine. BTI has reseached xB3 with bevacizumab for this same tumor. Could these drugs together, with Midech's and BTI's delivery technology, solve the problems of previous trials? "There are several potential reasons for the lack of activity with this combination. The dose of panobinostat used in this study was the maximum tolerated dose determined in our preliminary phase I study.19 Even though this dose is being explored in hematologic malignancies, it may be too low to achieve adequate tumor concentrations in the brain. This issue is compounded by the limited penetration of panobinostat across the blood-tumor barrier, a problem that is further exacerbated by combining it with bevacizumab, which reduces vascular permeability. In contrast, lomustine, which does penetrate the blood-tumor barrier, was successfully combined with bevacizumab for treatment of recurrent GBM.27 This difference underscores the need to combine bevacizumab with agents that have good blood-tumor barrier penetration. In addition, there are no preclinical data exploring the activity of the combination of panobinostat and bevacizumab in GBM models." Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma | Neuro-Oncology | Oxford Academic (oup.com)